Exenatide vs Tirzepatide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Exenatide
First GLP-1 receptor agonist approved for clinical use (2005), derived from the Gila monster venom peptide exendin-4. Available as twice-daily immediate-release (Byetta) and once-weekly extended-release (Bydureon BCise) formulations. Established the GLP-1 agonist drug class and provided the foundational clinical evidence for cardiovascular and metabolic benefits.
Full profileTirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class to activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. Approved as Mounjaro (type 2 diabetes) and Zepbound (obesity), it produces greater weight loss than any approved GLP-1 monotherapy in clinical trials.
Full profile| Exenatide | Tirzepatide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | Byetta, Bydureon, AC2993, exendin-4 | LY3298176, Mounjaro, Zepbound |
| Evidence | FDA-approved | FDA-approved |
| Dosing range | 5mcg–2mg (weekly ER) mcg, Twice daily (immediate-release) or once weekly (extended-release) | 2.5mg–15mg mg, Once weekly subcutaneous injection |
| Administration | Subcutaneous injection | Subcutaneous injection (abdomen, thigh, or upper arm) |
| Key side effects | Nausea (most common, especially initial weeks), Vomiting, Diarrhea, Injection site nodules (extended-release formulation) | Nausea (most common, especially during titration), Vomiting, Diarrhea, Constipation |
| Cited sources | 2 references | 4 references |
Key differences
- Administration: Exenatide — Subcutaneous injection; Tirzepatide — Subcutaneous injection (abdomen, thigh, or upper arm).
- Dosing units differ: Exenatide is dosed in mcg, Tirzepatide in mg — they operate at different scales.
- Frequency: Exenatide is typically Twice daily (immediate-release) or once weekly (extended-release); Tirzepatide is Once weekly subcutaneous injection.
- Research depth: this profile cites 2 sources for Exenatide vs 4 for Tirzepatide.
How each works
Exenatide
Exenatide was identified from Gila monster (Heloderma suspectum) venom as exendin-4, a peptide with ~53% homology to human GLP-1 but with DPP-4 resistance enabling longer activity. Clinical trials demonstrated HbA1c reductions of 0.8–1.0%, weight loss of 2–4kg, and cardiovascular safety (EXSCEL trial showed non-inferiority). The extended-release microsphere formulation achieved comparable efficacy with once-weekly dosing.
Tirzepatide
The SURMOUNT-1 trial (N=2539) demonstrated up to 22.5% mean body weight reduction over 72 weeks at the 15mg dose — the highest efficacy ever recorded for a pharmaceutical weight loss agent at time of publication. The dual mechanism leverages GIP's potentiation of insulin secretion and adipose tissue effects alongside GLP-1's appetite suppression and gastric motility slowing. Head-to-head data (SURMOUNT-5) shows tirzepatide outperforms semaglutide 2.4mg for weight loss.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.